(BPT) – Imagine waking up every day feeling utterly exhausted, no matter how much sleep you get. Now, add an unbearable itch that just won’t go away, dry eyes and mouth, and stomach pain. This is the ...

Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the autoimmune disease are anti-mitochondrial antibodies (AMA), present in approximately ...

While PBC progresses slowly and many patients do not experience symptoms during the early stages of disease, there are many symptoms to look out for. In later stages of disease, patients may ...

CHMP positive opinion for Iqirvo® (elafibranor) recommended for the treatment of primary biliary cholangitis, following FDA approval in June 2024 CHMP positive opinion for Kayfanda® (odevixibat) ...

DEAR DR. ROACH: I am an 85-year-old female who has had primary biliary cirrhosis of the liver for many years. I have been on 300 mg of ursodiol taken three times a day for all those years, with no ...

In patients with primary sclerosing cholangitis, biliary tract cancer is the leading cause of death. Yet very little is known about effective systemic treatments in these individuals. A new study ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi ® (seladelpar) ...

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

The European Commission has granted conditional approval for Ipsen's IQIRVO (elafibranor) for the treatment of primary biliary cholangitis in adults, marking the first new therapy for this condition ...

Findings showed a statistically significantly greater proportion of saroglitazar-treated patients achieved a biochemical response vs placebo (treatment difference, 48.5%; P .001). Topline data were ...